For studies involving human participants, authors should describe measures taken to obtain (1) approval by (regional/ national/ institutional or independent Ethics Committee or Review Board; and (2) informed consent from adult research participants; and (3) informed consent from parents or guardians, as well as the assent of children, that are study subjects. The age at which an individual may provide assent, or informed consent, may vary per regional and/ or national guidelines. Ensure confidentiality of subjects by refraining from mentioning participants' names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate that local and national regulations were followed for the care and use of laboratory animals was followed. The attestation by the authors that they have obtained local regulatory review and have adhered to local and national regulations regarding ethical treatment of human and animal subjects must be included in all research articles under the 'Materials and Methods' section.
If requested, authors must supply evidence of approval by a local Ethics Committee (for both human as well as animal studies). Animal experimental procedures shall be as humane as possible, and the details of anesthetics and analgesics used shall be clearly stated. The ethical standards of experiments must be in accordance with the guidelines provided by the CPCSEA and World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Humans for studies involving experimental animals and human beings, respectively). Cardiology Plus will not consider any paper that does not meet the requisite standards of ethics.
On submission, editors review all submitted manuscripts initially for suitability for formal review. Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message are rejected before proceeding for formal peer-review. Manuscripts that are unlikely to be of interest to the readers of the journal are also liable to be rejected at this stage.
Manuscripts that are found suitable for potential publication of the journal will be sent to a minimum of two independent expert reviewers to assess the scientific quality of the manuscript. Authors submitting manuscripts to
Cardiology Plus may propose suitable reviewers or oppose reviewers who may have competing interests. The proposed reviewers should not be affiliated with the same institutes as the contributor(s). However, the selection of these reviewers is at the sole discretion of the editor, who selects reviewers to reflect relevant expertise, diversity, and geographical backgrounds.
Peer reviewers have access to the submitted manuscript and any appendices included by the authors. If the paper is a randomized controlled trial, peer reviewers will also have access to the trial protocol. Peer review assists editors in their decision on whether to publish an article and helps authors revise and improve their manuscripts. Peer reviewers make suggestions for improvements, critique the analysis, point out relevant published work which is not yet cited, and provide recommendations to the authors and the editors. Please note that reviewers should provide feasible revision comments on the manuscripts and ensure that the articles are conducted properly, scientifically credible, got ethical approval, references cited applicably, and reported in accordance with the appropriate guidelines (e.g., the CARE guidelines for case reports). Detailed reviewer checklist, please see
here. At
Cardiology Plus, reviewers' comments are sent to the authors anonymously. Details of peer review including dates and peer review comments are not shared publicly. Reviewed articles are treated confidentially prior to their publication.
Based on at least two reviewers' comments, the managing editor makes a decision on the manuscript and conveys the comments and suggestions (rejection/major/minor/acceptance in manuscript) to the corresponding author. Please note that the corresponding author needs to provide a point-by-point response to reviewers' comments and submit a revised version of the manuscript. Manuscripts are accepted on the basis of quality, originality, significance, novelty, and importance for the field.
Manuscripts received from Editorial Board Members will be screened by the other Editorial Board members and sent to external peer reviewers. The Editorial Board Members, who submit manuscripts to the journal as authors or co-authors, will be excluded from publication decisions.
Manuscripts received from Editor-in-Chief will be handled by one of the Editorial Board members of the journal and will be sent to external peer reviewers. The contributing Editor-in-Chief will be excluded from decision-making of his/her manuscript.>
Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or whoever relate to products or services in which the editor has an interest. Any such submission is subject to the journal's standard procedures, with peer review handled independently of the relevant editor and their research groups.
The authors have the right to appeal if they have a genuine cause to believe that the editorial board has wrongly rejected the paper. If the authors wish to appeal against the editorial decision, they should email the editorial office (email: [email protected]) explaining in detail the reason for the appeal. The appeals will be acknowledged by the editorial office and will be investigated in an unbiased manner. The processing of appeals will be done within 6–8 weeks. While under appeal, the said manuscript should not be submitted to other journals. The final decision rests with the Editor-in-Chief of the journal. Second appeals are not considered.
Every article appearing in this journal will be published open access. This means that the article is universally and freely accessible via the internet in perpetuity, in an easily readable format immediately after publication. All articles published in
Cardiology Plus are No Article Publishing Charge (NAPC). The Editorial Office of
Cardiology Plus will pay to make the articles open access.
*All word limits are exclusive of references, figure legends, and text in tables.
Original Articles:
These include reports of randomized controlled trials or interventional studies, studies of screening and diagnostic tests, outcome studies, cost effectiveness analyses, case-control series, and surveys. Manuscripts of original articles comprising up to 8000 words (excluding Abstract, References and Tables) should be divided into the following sections: Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusion, Discussion, References, Table and Figure Legends. Each section shall include a heading identifying the particular section.
Abstract: 200 - 500 words
Keywords: 3 - 5 words
Introduction: State the purpose and summarize the rationale for the study or observation.
Methods: Include and describe the following:
Ethical Statement:
Please note that all submissions to editorial office involving human beings or animals should indicate the ethical statement in the main text.
1.
Human Experiments
For research involving human
experiments, authors should also state that the study conformed to the provisions of the Declaration of Helsinki (as revised in 2013), available at: https://www.wma.net/policies- post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects. And the article must include a statement in the
Methods section that ethical approval was obtained from institutional review board(s) or the ethics committee(s) (or a statement that it was not required and why), the number/ID of the approval(s), and a statement that the participants (or their parent or legal guardian in the case of participants under 18) gave informed consent before taking part in (or a statement that it was not required and why).
Suggested description:
(Prospective experiments) The trial was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The trial was approved by institutional/regional/national ethics/committee/ethics board of ******* (NO.: the approval number of ethics board; date: ) and registered with the *** Clinical Trial registry (No.: registration number, date: ). Informed consent was obtained from all individual participants.
(Retrospective experiments) The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013)
and approved by institutional/regional/national ethics/committee/ethics board of ******* (NO.: the approval number of ethics board; date: ) . Due to the retrospective nature of the study, informed consent was waived by institutional/regional/national ethics/committee/ethics board of *******.
2.
Animals Experiments
For any experiments involving animals, the authors must indicate the nature of the ethical review permissions, relevant licenses (e.g. Animal [Scientific Procedures] Act 1986), and national or institutional guidelines for the care and use of animals by which the research was conducted. Describe this information in the
Methods section of the main text.
Suggested description:
Experiments were performed under a project license (NO.: the license number; date: ) granted by institutional/regional/national ethics/committee/ethics board of *******, in compliance with ******* national or institutional guidelines for the care and use of animals. All efforts were made to minimize the number of animals used and their suffering.
Study design: Selection and Description of Participants: Clearly describe method used to select observational or experimental participants (patients or laboratory animals, including controls), including inclusion and exclusion criteria and a description of the source population. Technical Information: Identify the methods, apparatus (provide manufacturer's name and address in parentheses), and procedures in sufficient detail to enable others to reproduce the results. Give references to established methods, including statistical methods (see below); provide references and brief descriptions for methods that have been published but are not well known; describe new or substantially modified methods, give reasons for using them, and evaluate their limitations. Identify with specificity all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration.
Reports of randomized clinical trials should present information on all major study elements, including the protocol, assignment of interventions (methods of randomization, concealment of allocation to treatment groups), and the method of masking (blinding), based on the CONSORT Statement (http://www.consort-statement.org).
Statistics: Whenever possible quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Authors should report data that is lost to observation (such as, dropouts from a clinical trial). When data are summarized in the Results section, specify the statistical methods used to analyze them. Avoid non-technical uses of technical terms in statistics, such as 'random' (which implies a randomizing device), 'normal', 'significant', 'correlations', and 'sample'. Define statistical terms, abbreviations, and most symbols. Specify the computer software used. Use upper case italics (P 0.048). For all P values include the exact value and not less than 0.05 or 0.001. Mean differences in continuous variables, proportions in categorical variables and relative risks including odds ratios and hazard ratios should be accompanied by their confidence intervals.
Results: Present results in a logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Do not repeat in the text all the data in the tables or illustrations; emphasize or summarize only important observations. Extra- or supplementary materials and technical detail can be placed in an appendix where it will be accessible but will not interrupt the flow of the text; alternatively, it can be published only in the electronic version of the journal.
When data are summarized in the Results section, give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated and specify the statistical methods used to analyze them. Restrict tables and figures to those needed to sufficiently support and/or illustrate the conclusions of the manuscript. Use graphs as an alternative to tables with many entries; do not duplicate data in graphs and tables. Where scientifically appropriate, analyses of the data by variables such as age and sex should be included.
Discussion: Include strengths and limitations of the study (study question, study design, data collection, analysis and interpretation); interpretation and implications in the context of the totality of evidence (is there a systematic review to refer to, if not, could one be reasonably done here and now, what this study adds to the available evidence, effects on patient care and health policy, possible mechanisms); Controversies raised by the study; and future research directions (for this particular research collaboration, underlying mechanisms, clinical research).
Do not repeat in detail data or other material given in the Introduction or the Results section. In particular, authors should avoid making statements on economic benefits and costs unless the manuscript includes economic data and analyses. Avoid claiming priority and alluding to work that has not been completed. New hypotheses may be stated if needed; however, they should be clearly labeled as such. About 30 references may be included.
Conclusion: Include summary of key findings (primary outcome measures, secondary outcome measures, results as they relate to a prior hypothesis).
Review Articles:
Only individuals who have performed substantial work on the subject matter of the review or are considered experts in the field of review should author a Review Article. A short summary of the work done by the author(s) in the field of review should accompany the manuscript.
The prescribed word count is up to 8000 words excluding tables, references and abstract. The manuscript should have an unstructured Abstract (200 - 500 words) representing an accurate summary of the article. The section titles depend upon the topic reviewed. Authors submitting review articles should include a section describing the methods used for locating, selecting, extracting, and synthesizing data. These methods should also be summarized in the Abstract.
Meta Analysis:
The length of the article is about 5000 words (not including tables, figures, and references). The meta-analysis should have the following headings: Abstract (200 - 500 words), Keywords (3 - 5 words), Introduction, Methods, Results, Discussion, Reference, Tables, and Legends. The abstracts should be structured as follows: Background and Objectives, Methods, Results, and Conclusion.
Case Reports:
Case reports present clinical observations customarily collected in healthcare delivery settings. They have proved helpful in the identification of adverse and beneficial effects, the recognition of new diseases, unusual forms of common diseases, and the presentation of rare diseases.
Case reports can comprise up to 1500 words (excluding Abstract and References) and should have the following headings: Abstract (unstructured, 200 - 500 words), Keywords (3 - 5 words), Introduction, Timeline, Case Presentation (Patient Information, Clinical Findings, Diagnostic Assessment, Therapeutic Intervention, Follow-up and Outcome), Discussion, Conclusion.
We recommend a timeline in the form of a table or figure that gives the specific dates and times of important components of the case. This might include family and past medical history, genetic information, current symptoms, diagnostic test results, interventions, and events that occurred during follow-up. The timeline should show how the key events of the case unfolded. Please refer to the following example.
Time |
Events |
Nine months before presentation | Bone marrow cytology, immunological panel, and a platelet antibody test suggested immune thrombocytopenia, but treatment with glucocorticoid and gamma globulin was not effective. |
Two weeks before presentation | Recurrent chest pain and shortness of breath started. |
First week of hospital stay | Diagnosis of acute myocardial infarction with heart failure (48% LVEF) and very low platelet count of 10×10^9/L. Clopidogrel (75mg/day), statin, nitrate, β-blocker, spironolactone, furosemide and milrinone were given, and platelet count was monitored. |
Second weeks of hospital stay | Chest pain gradually subsided but left heart failure persisted. Coronary angiography showed 90% occlusion of the proximal left anterior descending artery with slow blood flow. A zotarolimus-eluting stent was implanted. ST segment normalized and heart failure improved. |
3-month follow-up | The patient had no shortness of breath or bleeding. Platelet count was 9×10^9/L. LVEF was 63%. |
8-month follow-up | Patient developed pneumonia and subsequent heart failure. Platelet count was 2×10^9/L, and the patient received platelet transfusion. Clopidogrel was discontinued. Ginkgo Leaf Tablet was initiated. |
12-month follow-up | No shortness of breath. No thrombotic event or bleeding. Platelet count at 6×10^9/L. |
16-month follow-up | Platelet count at 1×10^9/L; hemoglobin at 65 g/L. No apparent bleeding. The patient received platelet and red blood cell transfusion. Ginkgo Leaf Tablet was discontinued. |
We recommend authors to apply the CAse REport (CARE) guidelines checklist in preparing the manuscript of case reports, which is structured to correspond with key components of a case report and capture useful clinical information (including 'meaningful use' information mandated by some insurance plans).
Authors should also state that the study conformed to the provisions of the Declaration of Helsinki (as revised in 2013), available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects. The submission of a Case Report should be accompanied by written informed consent from the subject (or their parent/guardian) before publication. Please describe this information in the
Case Presentation section of the main text.
Suggested description:
The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and approved by institutional/regional/national ethics/committee/ethics board of ******* (NO.: the registration number of ethics board; date: ). Written informed consent was obtained from the patient (or their parent/guardian) for publication of this case report and accompanying images/videos. A copy of the written informed consent is available for review by the editorial office of this journal.
Letter to the Editor:
These should be short and decisive observations. They should preferably relate to articles previously published in
Cardiology Plus or views expressed in
Cardiology Plus. They should not be preliminary observations that need a later publication for validation. The letter can comprise up to 500 words and 5 references. A Letter to the Editor can be authored by up to four authors.
Others:
Editorial, Perspective, Opinion, Consensus and Guideline, Study Design are commissioned by the editorial board.
TOP
MANUSCRIPT PREPARATION AND FORMATTING INSTRUCTIONS
Manuscripts must be written in clear, grammatical English. Manuscripts not conforming to journal format will be returned to authors for modification. Do not add line numbers as the system will generate those when the PDF is built. Acceptable document file types for text and tables include .DOC and .DOCX; do not submit a PDF.
The submission/revision checklist for authors are here for download. Please refer to the checklist to double check when submit origin manuscript or revised manuscript.
Title page should be in an additional file but footnotes, abbreviations, and abstract must be included in the main body file.
The following elements are required for every submission:
Title: Include a descriptive title of the work; the title should not be a sentence. No proprietary or brand names for drugs or agents may be used in article titles.
Authors: Each author should provide the affiliation as the full name, department, institute, city, zip code, country.
Address for Correspondence: A current email and full mailing address must be provided.
Funding: Include disclosure of funding received for this work, especially details of funding from any of the following organizations: National Institutes of Health (NIH); Wellcome Trust; and Howard Hughes Medical Institute (HHMI). list all forms of support received by each author for this study.
Author Contributions: List each author's specific contributions to the work (see details above, under Authorship).
Conflict of Interest Statement: If the author(s) have nothing to disclose, please include the phrase, "Conflict of Interest Statement: The authors declare that they have no financial conflict of interest with regard to the content of this manuscript.".
Acknowledgments: The names of collaborators who are not listed as coauthors, or of any others who contributed to the manuscript. Where a medical writer or editorial assistant has been used to write or edit the article, the writer must be identified and named.
Data Sharing Statement: From September 30, 2022,
Cardiology Plus requires authors to include in any articles that report results derived from research data to include a Data Sharing Statement which should include information on where data supporting the results reported in the article can be found, including where applicable, hyperlinks to publicly archived datasets analyzed or generated during the study. If the research data are not publicly available, this must be stated in the manuscript along with any conditions for accessing the data.
Data Sharing Statement should take one of the following forms (or a combination of more than one if required for multiple types of research data):
1) The datasets generated during and/or analyzed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS]
2) The datasets generated during and/or analyzed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.
3) The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
4) Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
5) All data generated or analyzed during this study are included in this published article [and its supplementary information files].
6) The data that support the findings of this study are available from [third party name] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [third party name].
References:
Cardiology Plus uses
American Medical Association (AMA) style. References should begin on a separate page and numbered in the order in which they are cited in the text, where they are designated by superscript numbers placed outside periods and commas, and inside colons and semicolons. Only published works and manuscripts that have been accepted for publication should be listed in the References. Completed manuscripts submitted for publication may be cited as footnotes to the text. If these are subsequently accepted, the author may transfer them to the reference section in galley proof.
References Format: If there are three or more, only the first three followed by "et al." should be included. Titles of journal articles must be included, and abbreviation of journal names should conform to Index Medicus style.
For information on AMA style, please visit
http://www.amamanualofstyle.com.
Two authors:
[1] Ahmed KA, Xiang J. Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med. 2011; 15: 1458.
More than three authors:
[1] Ali JM, Bolton EM, Bradley JA, et al. Allorecognition pathways in transplant rejection and tolerance. Transplantation 2013; 96: 681.
Organization as author:
[1] CDC. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57: 1.
[2] Donation after Circulatory Death. British Transplant Society. Available at:
http://www.bts.org.uk/Documents/Guidelines. Accessed August 1, 2013.
Tables and Footnotes:
Photographs of tables are not acceptable. Type each table, double-spaced throughout (including column headings, footnotes, and data), on a separate page. Tables may be included as part of the Main Body file and placed after the References section. Number the tables in sequence in Arabic numerals and supply a concise, informative title for each one. Each column in the tables should carry a concise heading describing the data in the column. Use lowercase superscript letters to designate footnotes, and type the footnotes below the tables to which they refer. Tables are cited in the text in numerical order. Each abbreviation in the table should be explained in the footnotes and be able to be understood without consulting the text.
Like text, tables should be prepared using a standard word-processing program and may be included within the main body text document, or uploaded separately. Do not upload table files more than once (that is, in the main document and in separate files).
Acceptable document file types for tables include .DOC and .DOCX; do not submit PDF, XLS or XLSX type files.
Figures and Legends:
Figures should be uploaded in the highest resolution available. Legends should be supplied for all figures. They are numbered to correspond with the figures and typed double-spaced on a separate page. Figure legends for any supplemental figures being submitted are to be provided separately; see section, Supplemental Digital Content (SDC).
Acceptable Figure File Formats
- Do not embed figures into the main body file
- All final digital figures for accepted manuscripts must be submitted in EPS, TIFF, JPG. PowerPoint PPT format is permitted when the image resolution is very high.
- Each figure must be uploaded as a separate file.
- Histology figures must be in color.
- Monochrome images (such as line graphs) should be prepared at a resolution of 1200 DPI.
- Halftones images (black/white or color) should be prepared at a resolution of 300 DPI.
- Combination halftones (images containing both pictures and text labeling) should be prepared at 600 DPI.
- Color images must be saved as ''CMYK''. Images saved as ''RGB'' are not acceptable for printing.
- Your manuscript may be returned to you for correction if the images are of insufficient quality.
- Artwork submitted to the Journal will be checked for quality. Authors submitting a revised paper will have the opportunity to check the quality of their images and make the necessary changes. This step is required for all revisions.
Each figure should have a title. If a figure is composed of several part figures, please use A, B, C, etc., to mark on the upper left corner of the part figure. Meanwhile, Each part of the figure in the legend should be illustrated. The abbreviations in the figure should also be explained.
Please refer to the following format:
Figure 5: Illustration of BASE.
A, A slightly oversized compliant balloon (with a 1.1:1 or 1.2:1 ratio of balloon size to target vessel size) over a workhorse guidewire dilates the intended segment at 10-14 atm.
B, After proximal vessel dissection, a polymer-jacketed guidewire (such as the Fielder XT, Fighter, or Pilot 200) with the microcatheter is advanced to the proximal cap.
C, The wire is advanced by pushing, without rotation, to form a loop.
ADR: Antegrade dissection reentry, IVUS: Intravascular ultrasound
Supplemental Digital Content (SDC):
Authors may submit Supplemental Digital Content to supplement the information provided in the manuscript. It is preferable to include all significant figures and tables in the manuscript, since there is not a limit on the number of items in this online journal. Nonetheless, SDC may include the following types of content: text, tables, figures, references peripheral to information provided as SDC, audio, and video. SDC should be consecutively cited in the Main Body text of the submitted manuscript. SDC files will be available via URL(s) placed at the citation points within the article and are not copyedited by the publisher. Note that Journal policies for manuscript submission relating to peer review, patient anonymity, ethics, financial disclosure, copyright, and permissions also apply to SDC. Authors should mask patients' eyes and remove patients' names from supplemental digital content unless they obtain written consent from the patients and submit them as supplemental files at the time of the manuscript submission.
Format, File Type and Size Requirements: SDC must be provided in one Word or PowerPoint file. Each SDC in the file should have a visual header in the following name format (e.g., ''SDC, Figure 1''; ''SDC, Materials and Methods'') and a corresponding citation must appear in the Main Body text. Note that SDC is numbered separately from non-SDC material. If providing SDC figure(s), a figure legend should be included on the figure itself. When uploading SDC select ''Supplemental Digital Content'' as the file designation. For audio and video files, also include the author name, videographer, participants, length (minutes), and size (MB). Video files should be formatted with a 320x240 pixel minimum screen size. For each submission, the SDC file cannot exceed a total size of 10 MB.
TOP
ONLINE MANUSCRIPT SUBMISSION
New Submissions
Once the manuscript has been created, visit the submission site at https://www.editorialmanager.com/cardioplus to upload the manuscript. Once the manuscript has been vetted for compliance to the Journal's requirements, a manuscript number will be assigned to the submission. Failure to adhere to these guidelines will result in your manuscript being returned to you for correction. Faxed, scanned or emailed copies of manuscripts will not be accepted.
Revised Submissions
Mandatory Author Forms
Upon first revision, authors will be required to complete a License to Publish (LTP) form. LTP forms are required of every author listed on the submission. Please ensure each author's email address is properly listed on the footnotes page of your manuscript to avoid delays in reaching authors. Manuscripts will not pass to production without completed forms. LTP forms are available from the submission site homepage
https://www.cardiologyplus.org/contributors.
All revised submissions require a point-by-point response to the reviewers' comments. Please upload this document as file type Response to Reviewers.
Changes made in the revised manuscript should be indicated using highlighted, bold or underlined text. Upload both a Marked and a Clean version of the revised manuscript. File types are provided for both versions.
A requirement of all revisions is the artwork quality check as described above (see Figures and Legends).
Revised manuscripts should be submitted within the deadline specified in the decision letter. Please contact us for an extension of the due date if it is not possible to submit the revision within that period, or should you desire to withdraw the manuscript from further consideration.
Revisions should adhere to original specifications for the submission type. Sometimes changes made in response to the decision/critiques may bring the revised manuscript out of compliance (e.g., over the word count and/or table/figure limit) with original specifications. This may be allowed by the Editor, but must be noted in the point-by-point response.
Submitting Invited Videos
Authors may want or be invited to submit videos to the Journal's website. The videos will serve to emphasize key aspects of the research findings reported in their soon to be published manuscript. Please visit Stand Alone Video Format Requirements
https://bit.ly/VMxbrb to download full specifications and instructions for preparing these invited videos.
TOP
POST ACCEPTANCE
Page Proofs
The Editor will contact you when page proofs are ready for your review. The figures included on author's proofs are high resolution. Please inform the Editor immediately if you have any questions concerning the quality of the figures on the proofs. It is expected that the final manuscript sent to the Editor is indeed the final version, so few changes should be required at proof stage.
Copyright
Cardilogy Plus is the owner of all copyrights to any articles published in the journal.
Creative Commons Licenses
Open access articles will be freely available to read, download and share from the time of publication. A CC user license manages the reuse of the article (see http://www.wkopenhealth.com/openaccessfaq.php). Articles are published under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND) which allows readers to disseminate and reuse the article, as well as share and reuse of the scientific material. It does not permit commercial exploitation or the creation of derivative works without specific permission. To view a copy of this license visit
https://creativecommons.org/licenses/by-nc-nd/4.0/
Editorial Office Contacts
The Editorial Office is pleased to answer any questions about preparing your manuscript in accordance with our guidelines. Presubmission inquiry, please contact
[email protected]. Follow-up status of submitted manuscript, please contact
[email protected].
Submit a manuscript:
https://www.editorialmanager.com/cardioplus
TOP
